(19)
(11) EP 4 493 695 A2

(12)

(88) Date of publication A3:
19.10.2023

(43) Date of publication:
22.01.2025 Bulletin 2025/04

(21) Application number: 23771609.7

(22) Date of filing: 15.03.2023
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
A61P 35/00(2006.01)
 A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 2310/14; C12N 2310/321; C12N 2310/322; C12N 2310/315; C12N 2310/3125; C12N 2310/351; C12N 15/1135; C12N 2320/31; C12N 2310/11; A61K 31/7125; A61K 45/06
 
C-Sets:
  1. C12N 2310/321, C12N 2310/3521;
  2. C12N 2310/322, C12N 2310/3533;
  3. A61K 31/7125, A61K 2300/00;
(86) International application number:
PCT/US2023/064381
(87) International publication number:
WO 2023/178141 (21.09.2023 Gazette 2023/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 15.03.2022 US 202263320163 P

(71) Applicant: Dicerna Pharmaceuticals, Inc.
Lexington, Massachusetts 02421 (US)

(72) Inventors:
  • GANESH, Shanthi
    Lexington, Massachusetts 02421 (US)
  • ABRAMS, Marc
    Lexington, Massachusetts 02421 (US)

(74) Representative: Holm, Signe Hoeg et al
Novo Nordisk A/S Corporate Patents Novo Allé
2880 Bagsværd
2880 Bagsværd (DK)

   


(54) COMBINATION OF STAT3 TARGETING OLIGONUCLEOTIDES AND PD-L1 INHIBITORS